Boundless Bio is a biotechnology company focused on interrogating a novel area of cancer biology, extrachromosomal DNA (ecDNA), to deliver transformative therapies to patients with previously intractable cancers.
| Date | Amount | Type | Investors | Valuation |
|---|---|---|---|---|
| 09/19/19 | $46,400,000 | Series A |
Alexandria Venture Investments ARCH Venture Partners  Boxer Capital City Hill Ventures GT Healthcare Capital Partners Vertex Ventures | undisclosed |
| 04/28/21 | $105,000,000 | Series B |
ARCH Venture Partners City Hill Ventures Fidelity Management & Research Company GT Healthcare Capital Partners Logos Capital Nextech Ventures PFM Health Sciences RA Capital Management Redmile Group Surveyor Capital Vertex Ventures Wellington Management Company | undisclosed |
